ABSTRACT

The direct oral thrombin inhibitor dabigatran has a predictable anticoagulant effect and may be an alternative therapy to warfarin for patients who haveacute venous thromboembolism. This study aimed to compare the safety and efficacyof Dabigatran vs Warfarin in patients with deep vein thrombosis (DVT). An ambispective study was conducted on patients with DVT. Patients were randomly received dabigatran or warfarin for treatment of DVT by the doctor. Demographic details, drug treatment, medical history, presenting complaints, and diagnosis were recorded in CRF. Descriptive statistical analysis was done using MS Excel. In total, 60 patients with DVT were divided into 2 treatment groups (30 to dabigatran and 30 to warfarin). The duration of treatment was 6 months. The majority of the 32 (53.4%) had Poplitial femoral DVT. Dabigatran treatment group 26 (86.6%) showed better recanalization at the end of the 6-month treatment duration while in Warfarin there were 15 (50%) patients. Except for patients who had pulmonary embolism even on treatment, all of the safety and efficacy parameters had shown significant differences (p < 0.05). In acute DVT, dabigatran showed significant evidence of clinical safety and efficacy compared to warfarin with a better safety profile and no laboratory monitoring. Keywords: Deep Vein Thrombosis, Safety, Efficacy, Dabigatran, Warfarin
Publication date: 01/05/2024

https://ijbpas.com/pdf/2024/May/MS_IJBPAS_2024_7997.pdf

Download PDF
https://doi.org/10.31032/IJBPAS/2024/13.5.7997